British Diagnostics Firm Develops More Accurate Fetal Health Screen

fetus health test DNA

A lab kit from British diagnostics company Angle could make non-invasive fetal health screens more accurate by analyzing whole fetal cells in the mother’s blood.

To screen your unborn baby for genetic conditions, the most accurate current option is invasive techniques such as amniocentesis. These techniques take samples directly from the womb that contain fetal cells and allow screening of the fetal genome for genetic conditions, but can risk miscarriage.

Non-invasive techniques that rely on a blood sample taken from the mother are also available. Instead of whole cells, they screen fetal DNA fragments that are passed into the mother’s bloodstream. These techniques can accurately predict more common chromosomal abnormalities, such as Down Syndrome, but for other conditions, such as some caused by deletion mutations, their accuracy is limited.

Current cell-free fetal DNA … techniques cannot provide genetic information on all types of potential abnormalities,” Andrew Newland, Angle’s CEO, told me. “[They] also cannot differentiate maternal from fetal DNA, can be costly, and have long turnaround times.

fetal health test lab kit

To improve the accuracy of non-invasive techniques, Angle designed a lab kit that can harvest whole fetal cells which circulate in the mother’s blood. As it uses whole cells, it could allow a non-invasive analysis of the whole fetal genome, making these tests way more accurate.

In a pilot study using blood samples from 19 pregnant mothers, Angle’s kit was able to predict the fetus’s sex and identify if it had genetic signs of Down’s syndrome, as a demonstration of the test’s accuracy. With further development, this technique could be used to detect many more genetic conditions.

Angle now plans to partner with a company that will help develop and commercialize the fetal health test. In the meantime, the company is developing another test, based on the same technology, for analyzing circulating tumor cells in the patient’s blood in cancers such as breast and prostate cancer.

There are territorial competitors in the non-invasive fetal screening market. US giant Illumina launched its maternal blood test in Europe last year and has a habit of suing other companies developing similar technology. However, as Illumina’s technology screens fetal DNA, rather than whole cells in maternal blood, Angle should be in the clear.

Images from Shutterstock

Explore other topics: United Kingdom

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.

Suggested Articles

Show More